VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | IMpower133: atezolizumab, carboplatin plus etoposide for SCLC

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses the IMpower133 (NCT02763579) trial updated overall survival (OS) analysis of first-line atezolizumab plus carboplatin plus etoposide in extensive-stage small-cell lung cancer SCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter